More biosimilar use could've saved Medicare and beneficiaries $84M in 2019, HHS OIG says
In the nearly 7 years since biosimilars were first approved in the US, the story has been one of lackluster uptake, amid a growing familiarity …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
